<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Black Diamond Therapeutics Inc — News on 6ix</title>
    <link>https://6ix.com/company/black-diamond-therapeutics-inc</link>
    <description>Latest news and press releases for Black Diamond Therapeutics Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/black-diamond-therapeutics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354be678dffbe2df0e54a5.webp</url>
      <title>Black Diamond Therapeutics Inc</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc</link>
    </image>
    <item>
      <title>Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-announces-oral-presentation-of-silevertinib-phase-2-data-in-frontline-egfrm-nsclc-patients-at-the-2026-asco-annual-meeting-8</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-announces-oral-presentation-of-silevertinib-phase-2-data-in-frontline-egfrm-nsclc-patients-at-the-2026-asco-annual-meeting-8</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
      <pubDate>Mon, 16 Mar 2026 20:01:00 GMT</pubDate>
      <description>Clinical update on track for Q2 2026 for Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, including preliminary DOR and PFS data in frontline settingCompany is preparing to initiate a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFR altered GBM in Q2 2026 Cash, cash equivalents, and investments of $128.7 million as of December 31, 2025, expected to be sufficient to fund operations into 2H of 2028 CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSW</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-announces-preliminary-120100579</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-announces-preliminary-120100579</guid>
      <pubDate>Wed, 03 Dec 2025 12:01:00 GMT</pubDate>
      <description>Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals observed to datePFS data for 1L NSCLC patients expected in Q2 2026; Company continues to explore partnership opportunities for pivotal development of silevertinibBased on encouraging CNS activity of silevertinib in multiple trials across NSCLC and GBM, Company plans to initiate a r</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-host-webcast-210100319</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-host-webcast-210100319</guid>
      <pubDate>Tue, 02 Dec 2025 21:01:00 GMT</pubDate>
      <description>Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET. Webcast information The webcast can be accessed</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-participate-upcoming-210100335</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-participate-upcoming-210100335</guid>
      <pubDate>Thu, 06 Nov 2025 21:01:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: Stifel Healthcare Conference fireside chat at 9:20am ET on Tuesday, November 11, 2025Gugg</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-third-123000270</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-third-123000270</guid>
      <pubDate>Thu, 06 Nov 2025 12:30:00 GMT</pubDate>
      <description>ORR and preliminary duration of treatment data for the Phase 2 trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for this quarter Cash, cash equivalents, and investments of $135.5 million as of September 30, 2025; expected to be sufficient to fund operations into Q4 of 2027 CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogeni</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-second-113000499</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-second-113000499</guid>
      <pubDate>Thu, 07 Aug 2025 11:30:00 GMT</pubDate>
      <description>Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025Exploring partnership opportunities to advance pivotal development of silevertinib in NSCLC and GBMPlan to meet with FDA regarding 1L NSCLC development path in 1H 2026, when PFS data becomes availableCash, cash equivalents, and investments of $142.8 million as of June 30, 2025; expected to be sufficient to fund operations in</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-participate-jefferies-120000162</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-participate-jefferies-120000162</guid>
      <pubDate>Thu, 29 May 2025 12:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025 in New York, NY. In addition, the company will host one-on-one meetings with investors on t</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-first-200500728</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-first-200500728</guid>
      <pubDate>Mon, 12 May 2025 20:05:00 GMT</pubDate>
      <description>Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma patients with EGFR alterations initiated in Q1 2025Cash, cash equivalents, and investments of $152.4 million as of March 31, 2025; expected to be sufficient to fund operations into Q4 of 2027 CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical</description>
    </item>
    <item>
      <title>Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/servier-black-diamond-therapeutics-announce-110000115</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/servier-black-diamond-therapeutics-announce-110000115</guid>
      <pubDate>Wed, 19 Mar 2025 11:00:00 GMT</pubDate>
      <description>The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF alterations, in solid tumors, including non-small cell lung cancerBlack Diamond will receive an upfront payment of $70 million and up to $710 million in development and commercial sales milestone payments plus royalties SURESNES, France and C</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-fourth-210100750</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-fourth-210100750</guid>
      <pubDate>Thu, 06 Mar 2025 21:01:00 GMT</pubDate>
      <description>Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored “window of opportunity” trial into newly diagnosed glioblastoma patients with EGFR aberrations expected in Q1 2025Cash, cash equivalents, and investments of $98.6 million as of December 31, 2024, expected to be sufficient to fund operations into Q4 2026 CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX)</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-update</guid>
      <pubDate>Tue, 05 Nov 2024 05:00:00 GMT</pubDate>
      <description>Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-announces-restructuring-plan-to-focus-resources-on-bdtx-1535-and-extend-cash-runway</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-announces-restructuring-plan-to-focus-resources-on-bdtx-1535-and-extend-cash-runway</guid>
      <pubDate>Mon, 07 Oct 2024 04:00:00 GMT</pubDate>
      <description>Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-announces-initial-phase-2-data-demonstrating-robust-anti-tumor-activity-of-bdtx-1535-in-patients-with-recurrent-egfrm-nsclc-who-present-with-a-broad-spectrum-of-classical-non-classical-and-c797s-resistance-mutations</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-announces-initial-phase-2-data-demonstrating-robust-anti-tumor-activity-of-bdtx-1535-in-patients-with-recurrent-egfrm-nsclc-who-present-with-a-broad-spectrum-of-classical-non-classical-and-c797s-resistance-mutations</guid>
      <pubDate>Mon, 23 Sep 2024 04:00:00 GMT</pubDate>
      <description>BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed Preliminary ORR of 42% in</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-to-host-webcast-presentation-of-initial-phase-2-bdtx-1535-data-in-patients-with-recurrent-egfrm-nsclc</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-to-host-webcast-presentation-of-initial-phase-2-bdtx-1535-data-in-patients-with-recurrent-egfrm-nsclc</guid>
      <pubDate>Sun, 22 Sep 2024 04:00:00 GMT</pubDate>
      <description>Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX),</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-presents-real-world-treatment-practices-and-patient-outcomes-in-newly-diagnosed-nsclc-patients-with-non-classical-mutations-at-the-european-society-for-medical-oncology-esmo-congress-2024</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-presents-real-world-treatment-practices-and-patient-outcomes-in-newly-diagnosed-nsclc-patients-with-non-classical-mutations-at-the-european-society-for-medical-oncology-esmo-congress-2024</guid>
      <pubDate>Sat, 14 Sep 2024 04:00:00 GMT</pubDate>
      <description>Treatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update</guid>
      <pubDate>Tue, 06 Aug 2024 04:00:00 GMT</pubDate>
      <description>Initial Phase 2 data of BDTX-1535 in 2L/3L patients with EGFRm NSCLC on track for later in Q3 2024On track to announce initial Phase 2 data of BDTX-1535 in 1L</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-presents-promising-bdtx-1535-clinical-data-in-patients-with-recurrent-glioblastoma-at-2024-american-society-of-clinical-oncology-asco-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-presents-promising-bdtx-1535-clinical-data-in-patients-with-recurrent-glioblastoma-at-2024-american-society-of-clinical-oncology-asco-annual-meeting</guid>
      <pubDate>Sat, 01 Jun 2024 04:00:00 GMT</pubDate>
      <description>Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-update</guid>
      <pubDate>Thu, 09 May 2024 04:00:00 GMT</pubDate>
      <description>Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting</title>
      <link>https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-announces-presentations-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/black-diamond-therapeutics-inc/news/black-diamond-therapeutics-announces-presentations-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting</guid>
      <pubDate>Wed, 24 Apr 2024 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey</description>
    </item>
  </channel>
</rss>